Breakneck expansion and new spending have put life sciences — and the developers and brokers who build and sell lab space and specialized offices — in an enviable position. But the sector is missing one key ingredient. “Today we have immense amounts of capital, lots of focus and a big market," Cushman & Wakefield Director of Business Intelligence Brendan Carroll said. "What’s lagging is the skill."
The maturity of the life sciences market has lowered the perceived risk of investment, inviting new ventures and new capital. According to S&P Global Market Intelligence, biotech alone raised $20B in private equity and venture capital, and UBS found healthcare represented 14% of all deal activity in private equity last… Read the full story here. |